C12N 2710/16633
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/16633 (Use of viral protein as therapeutic agent other than vaccine) appears on 30 US grants and 47 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 47
- Assignees
- 26
- Inventors
- 58
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 2 | 3 |
| 2016 | 0 | 3 |
| 2017 | 2 | 0 |
| 2018 | 1 | 4 |
| 2019 | 0 | 7 |
| 2020 | 6 | 7 |
| 2021 | 2 | 3 |
| 2022 | 5 | 4 |
| 2023 | 1 | 7 |
| 2024 | 4 | 5 |
| 2025 | 4 | 1 |
| 2026 | 3 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Replication-competent recombinant herpes simplex virus type 1 (HSV-1) comprising deletions in the ICP6 and IR regions14 Apr 2026US 12,600,955 B1Sungkwang Medical Foundation
- Oncolytic virus strain3 Mar 2026US 12,564,633 B2Replimune Limited
- Melanoma canine vaccine compositions and methods of use thereof10 Feb 2026US 12,544,433 B2The Wistar Institute
- Modified oncolytic virus11 Nov 2025US 12,465,639 B2Replimune Limited GB
- Modified oncolytic virus4 Nov 2025US 12,458,696 B2Replimune Limited
- Viral Vectors for Cancer Therapy30 Apr 2026US 2026/0115327 A1Krystal Biotech, Inc.
- Engineered virus20 Nov 2025US 2025/0352646 A1Replimune Limited
- Viral Vectors for Cancer Therapy5 Dec 2024US 2024/0398994 A1Krystal Biotech, Inc.
- Compositions and methods for therapeutic or vaccine delivery28 Nov 2024US 2024/0390474 A1GenVivo, Inc.
- Oncolytic virus strain12 Sep 2024US 2024/0301365 A1Replimune Limited
Most cited
By later US patents
- Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof14US 9,157,071 B2Alma Mater Studiorum - Università di Bologna · 2015
- Oncolytic virus strain11US 10,570,377 B2Replimune Limited · 2020
- Modified oncolytic virus11US 10,612,005 B2Replimune Limited · 2020
- Use of an oncolytic virus for the treatment of cancer10US 10,626,377 B2Replimune Limited · 2020
- Engineered virus10US 10,947,513 B2Replimune Limited · 2021